Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 3, Issue , 2011, Pages 1263-1281

  Xiao, Zeyu ^b   Frieder, Jillian ^b   Teply, Benjamin A ^b   Farokhzad, Omid C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

Aptamer; Drug delivery; Internalization; Targeted cancer therapy

Indexed keywords

EID: 84887185542     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch39     Document Type: Chapter

References (91)

1. Langer, R. (1998) Drug delivery and targeting. Nature, 392 (Suppl. 6679), 5-10.
2. Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 5, 161-171.
3. Davis, M.E., Chen, Z.G., and Shin, D.M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 7, 771-782.
4. Boerman, O.C. et al. (1999) Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res., 59, 4400-4405.
5. Paganelli, G. et al. (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med., 26, 348-357.
6. Axworthy, D.B. et al. (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA, 97, 1802-1807.
7. Adams, G.P. and Schier, R. (1999) Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods, 231, 249-260.
8. Wu, A.M. et al. (1996) Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology, 2, 21-36.
9. Alexis, F. et al. (2008) HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem, 3, 1839-1843.
10. Farokhzad, O.C. et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 103, 6315-6320.
11. Farokhzad, O.C. et al. (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res., 64, 7668-7672.
12. Farokhzad, O.C., Karp, J.M., and Langer, R. (2006) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv., 3, 311-324.
13. Peer, D. et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2, 751-760.
14. Farokhzad, O.C. (2008) Nanotechnology for drug delivery: the perfect partnership. Expert Opin. Drug Deliv., 5, 927-929.
15. Farokhzad, O.C. et al. (2006) Drug delivery systems in urology - getting ''smarter''. Urology, 68, 463-469.
16. Farokhzad, O.C. and Langer, R. (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev., 58, 1456-1459.
17. Farokhzad, O.C. and Langer, R. (2009) Impact of nanotechnology on drug delivery. ACS Nano, 3, 16-20.
18. Keefe, A.D., Pai, S., and Ellington, A. (2010) Aptamers as therapeutics. Nat. Rev. Drug Discov., 9, 537-550.
19. Colas, P. et al. (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature, 380, 548-550.
20. Bickle, M.B., Dusserre, E., Moncorge, O., Bottin, H., and Colas, P. (2006) Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures. Nat. Protoc., 1, 1066-1091.
21. Colas, P. (2008) The eleven-year switch of peptide aptamers. J. Biol., 7, 2.
22. Baines, I.C. and Colas, P. (2006) Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today, 11, 334-341.
23. Ellington, A.D. and Szostak, J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
24. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
25. Bouchard, P.R., Hutabarat, R.M., and Thompson, K.M. (2010) Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol., 50, 237-257.
26. Mayer, G. (2009) The chemical biology of aptamers. Angew. Chem. Int. Ed. Engl., 48, 2672-2689.
27. Bagalkot, V., Farokhzad, O.C., Langer, R., and Jon, S. (2006) An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed., 45, 8149-8152.
28. Bagalkot, V. et al. (2007) Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett., 7, 3065-3070.
29. Chen, C.H. et al. (2008) Aptamer-based endocytosis of a lysosomal enzyme. Proc. Natl. Acad. Sci. USA, 105, 15908-15913.
30. Chu, T.C. et al. (2006) Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res., 66, 5989-5992.
31. Chu, T.C., Twu, K.Y., Ellington, A.D., and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res., 34, e73.
32. McNamara, J.O. II et al. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24, 1005-1015.
33. Tsui, P., Rubenstein, M., and Guinan, P. (2005) Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J. Biomed. Biotechnol., 2005, 287-290.
34. Tasch, J., Gong, M., Sadelain, M., and Heston, W.D. (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol., 21, 249-261.
35. Liu, H. et al. (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res., 58, 4055-4060.
36. Lupold, S.E., Hicke, B.J., Lin, Y., and Coffey, D.S. (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res., 62, 4029-4033.
37. Levy-Nissenbaum, E., Radovic-Moreno, A.F., Wang, A.Z., Langer, R., and Farokhzad, O.C. (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 26, 442-449.
38. Yan, A.C. and Levy, M. (2009) Aptamers and aptamer targeted delivery. RNA Biol., 6, 316-320.
39. Thiel, K.W. and Giangrande, P.H. (2009) Therapeutic applications of DNA and RNA aptamers. Oligonucleotides, 19, 209-222.
40. Kraus, E., James, W., and Barclay, A.N. (1998) Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J. Immunol., 160, 5209-5212.
41. Zhou, J. et al. (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res., 37, 3094-3109.
42. Dey, A.K., Griffiths, C., Lea, S.M., and James, W. (2005) Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA, 11, 873-884.
43. Dey, A.K. et al. (2005) An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol., 79, 13806-13810.
44. Hicke, B.J. et al. (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem., 276, 48644-48654.
45. Cao, Z. et al. (2009) Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed., 48, 6494-6498.
46. Ferreira, C.S., Cheung, M.C., Missailidis, S., Bisland, S., and Gariepy, J. (2009) Phototoxic aptamers selectivelyenter and kill epithelial cancer cells. Nucleic Acids Res., 37, 866-876.
47. Dhar, S., Gu, F.X., Langer, R., Farokhzad, O.C., and Lippard, S.J. (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 105, 17356-17361.
48. Dassie, J.P. et al. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 27, 839-849.
49. Wullner, U. et al. (2008) Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets, 8, 554-565.
50. Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E., and Triche, T.J. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res., 65, 8984-8992.
51. Zhou, J., Li, H., Li, S., Zaia, J., and Rossi, J.J. (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther., 16, 1481-1489.
52. Huang, Y.F. et al. (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem, 10, 862-868.
53. Tong, G.J., Hsiao, S.C., Carrico, Z.M., and Francis, M.B. (2009) Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc., 131, 11174-11178.
54. Sawyers, C.L. (2008) The cancer biomarker problem. Nature, 452, 548-552.
55. Daniels, D.A., Chen, H., Hicke, B.J., Swiderek, K.M., and Gold, L. (2003) A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. USA, 100, 15416-15421.
56. Guo, K.T., Ziemer, G., Paul, A., and Wendel, H.P. (2008) CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci., 9, 668-678.
57. Fang, X. and Tan, W. (2009) Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res., 43, 48-57.
58. Shangguan, D., Cao, Z.C., Li, Y., and Tan, W. (2007) Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem., 53, 1153-1155.
59. Xiao, Z., Shangguan, D., Cao, Z., Fang, X., and Tan, W. (2008) Cell-specific internalization study of an aptamer from whole cell selection. Chemistry, 14, 1769-1775.
60. Raddatz, M.S. et al. (2008) Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. Engl., 47, 5190-5193.
61. Kulbachinskiy, A.V. (2007) Methods for selection of aptamers to protein targets. Biochemistry., 72, 1505-1518.
62. Zhou, J. and Rossi, J.J. (2010) Aptamer-targeted cell-specific RNA interference. Silence, 1, 4.
63. Chu, T., Ebright, J., and Ellington, A.D. (2007) Using aptamers to identify and enter cells. Curr. Opin. Mol. Ther., 9, 137-144.
64. Stirpe, F., Olsnes, S., and Pihl, A. (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J. Biol. Chem., 255, 6947-6953.
65. Better, M. et al. (1994) Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties. J. Biol. Chem., 269, 9644-9650.
66. Huang, Y.F., Chang, H.T., and Tan, W. (2008) Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal. Chem., 80, 567-572.
67. Huang, Y.F., Sefah, K., Bamrungsap, S., Chang, H.T., and Tan, W. (2008) Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir, 24, 11860-11865.
68. Cullen, B.R. (2002) RNA interference: antiviral defense and genetic tool. Nat. Immunol., 3, 597-599.
69. Sioud, M. (2005) On the delivery of small interfering RNAs into mammalian cells. Expert Opin. Drug Deliv., 2, 639-651.
70. Xie, F.Y., Woodle, M.C., and Lu, P.Y. (2006) Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today, 11, 67-73.
71. Shi, H., Hoffman, B.E., and Lis, J.T. (1999) RNA aptamers as effective protein antagonists in a multicellular organism. Proc. Natl. Acad. Sci. USA, 96, 10033-10038.
72. Santulli-Marotto, S., Nair, S.K., Rusconi, C., Sullenger, B., and Gilboa, E. (2003) Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res., 63, 7483-7489.
73. McNamara, J.O. et al. (2008) Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest., 118, 376-386.
74. Dollins, C.M. et al. (2008) Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol., 15, 675-682.
75. Griffin, L.C., Tidmarsh, G.F., Bock, L.C., Toole, J.J., and Leung, L.L. (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood, 81, 3271-3276.
76. '-modified hammerhead ribozymes. Science, 253, 314-317.
77. Chow, W.H., Dong, L.M., and Devesa, S.S. (2010) Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol., 7, 245-257.
78. Ng, E.W. et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 5, 123-132.
79. '-O-methyl aptamer to VEGF. Chem. Biol., 12, 25-33.
80. Soutschek, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
81. Rusconi, C.P. et al. (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol., 22, 1423-1428.
82. Hicke, B.J. and Stephens, A.W. (2000) Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest., 106, 923-928.
83. Lister-James, J., Moyer, B.R., and Dean, T. (1996) Small peptides radiolabeled with 99mTc. Q. J. Nucl. Med., 40, 221-233.
84. Hicke, B.J. et al. (2006) Tumor targeting by an aptamer. J. Nucl. Med., 47, 668-678.
85. Jason, T.L., Koropatnick, J., and Berg, R.W. (2004) Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol., 201, 66-83.
86. Levin, A.A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta, 1489, 69-84.
87. Henry, S.P. et al. (2002) Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol., 2, 1657-1666.
88. Lenert, P.S. (2010) Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm., 2010, 986596.
89. Yu, D. et al. (2009) Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J. Med. Chem., 52, 5108-5114.
90. Cooper, C.L. et al. (2008) Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. J. Immune Based Ther. Vaccines, 6, 3.
91. Krieg, A.M. (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161-167.